FPIs invest Rs 22,038 crore in February so far amid post-Budget cheer

Overseas investors poured in Rs 20,593 crore into equities and Rs 1,445 crore in the debt segment, taking the total net investment to Rs 22,038 crore during February 1-12.

PTI

February 14, 2021 / 15:45 IST

Representative Image

Continuing their buying trend, foreign portfolio investors (FPIs) have pumped in a net Rs 22,038 crore into the Indian markets in February so far amid positive sentiments around the Union Budget. According to depositories data, overseas investors poured in Rs 20,593 crore into equities and Rs 1,445 crore in the debt segment, taking the total net investment to Rs 22,038 crore during February 1-12.

In January, FPIs were net investors to the tune of Rs 14,649 crore. Himanshu Srivastava, associate director – manager research, Morningstar India, attributed the strong inflows in February to "the positive sentiments around the equity markets after the Union Budget."

FPIs net buyers at Rs 14,649 crore in January

The government's efforts in the Budget to bring the economy back on track have been lauded by investors, he added. Besides, there are other indicators that support FPI flows into the equity markets like continuous decline in the case count, rollout of vaccines, growth in earnings and measures taken by the government to boost the economy, Srivastava said.

V K Vijayakumar, chief investment strategist at Geojit Financial Services, noted that there is sectoral rotation happening in the market now. In 2020, pharma sector was a preferred choice and the sector did very well, while banking stocks underperformed due to potential non-performing assets concerns.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show